Диссертация (1140910), страница 17
Текст из файла (страница 17)
– P. 25–30.70. Laterza O.F., Price C.P., Scott M.G. Cystatin C: an improved estimator ofglomerular filtration rate? // Clin Chem. – 2002. – N.48. – P. 699 –707.71. Levey A, Atkins R, Coresh J et al. Chronic kidney disease as a globalpublic health problem: approaches and initiatives–a position statement fromKidney Disease Improving Global Outcomes // Kidney International. –2007. – N.72.
– P. 247-259.72.Levey A, de Jong P, CoreshJ, et al. Lower estimated glomerular filtrationrate and higher albuminuria are associated with all-cause and cardiovascular101mortality. A collaborative meta-analysis of high-risk population cohorts //Kidney Int. – 2011. – N.80. – P. 17–28.73. Levey AS, de Jong PE, Coresh J et al. The definition, classification andprognosis of chronic kidney disease: a KDIGO Controversies Conferencereport // Kidney Int.
– 2010. http:/www.kidney-international.org74. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification ofсhronic kidney disease: a position statement from Kidney Disease:Improving Global Outcomes (KDIGO) // Kidney Int. – 2005. – v.67. – N.6.– P. 2089-20100.75. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimateglomerular filtration rate // Ann Intern Med. – 2009.
– N.150. – P. 604-612.76.Lin M-Y., Chiu Y-W., Lee C-H., Yu H-Y. et al. Factors Associated withCKD in the Elderly and Nonelderly Population // Clin J Am Soc Nephrol. –2013. – Vol.8, N.1. – P. 33–40.77. Locatelli F., Del Vecchio L., D'Amico M., Andrulli S. Is it the agent or thepressure level that matters for renal protection in chronic nephropathies? //J.Am. Soc. Nephrol. - 2002.
- Vol. 13, Suppl. 18. - P. 36-42.78. Locatelli F., Del Vecchio L., Pozzoni P. The importance of early detectionof chronic kidney disease // Nephrol. Dial. Transplant. - 2002. - Vol. 17,Suppl. 11.-P. 2-7.79. Locatelli F., Del Vecchio L., Pozzoni P. The importance of early detectionof chronic kidney disease // Nephrol.
Dial. Transplant. - 2002. - Vol. 17,Suppl. 11.- P. 2-7.80. Loew M., Hoffmann M. M., Koenig W., Brenner H., Rothenbacher D.Genotype and plasma concentrationof cystatin C in patients with coronaryheart disease and risk for secondary cardiovascular events // Arterioscler.Thromb. Vasc. Biol. – 2005. – Vol. 25, №7. – P. 1470–1474.10281.Lofberg H, Grubb A.
Quantitation of gamma-trace in human biological fluids: indications for production in the central nervous system // Scand JClin Lab Invest. – 1979. –N.39. – P. 619–26.82.Lotan Y., Daudon M., Bruyère F., Talaska G. et al. Impact of fluid intake inthe prevention of urinary system diseases: a brief review // Curr. Opin.Nephrol.
Hypertens. – 2013. – Vol. 22, – N.1. – P. 1-10.83.McClellan WM, Ramirez SP, Jurkovitz C. Screening for chronic kidneydisease: Unresolved isues // J Am Soc Nephrol. – 2003. – N.14, Suppl.2. –P. 81-87.84. National Collaborating Centre for Chronic Conditions, Chronic kidneydisease: National clinical guideline for early identification and managementin adults in primary and secondary care.
– 2008, Royal College ofPhysicians: London.85. National Kidney Foundation. K/DOQI clinical practice guidelines forchronic kidney disease: evaluation, classification, and stratification //American Journal of Kidney Diseases. – 2002. – N.39. – P. 266.86.National Kidney Foundation: K/DOQI clinical practice guidelines forchronic kidney disease: Evaluation, classification and stratification // Am JKidney Dis. – 2002. – N.39, Suppl.2.
– P. 246.87. Newman D.J., Thakkar H., Edwards R.G., Wilkie M., White T, GrubbA.O., Price C.P. Serum cystatin C measured by automated immunoassay: amore sensitive marker of changes in GFR than serum creatinine // KidneyInt. – 1995. – N.47. – P. 312–318.88. Nickolas TL, Frisch GD, Opotowsky AR et al. Awareness of kidneydisease in the US population: findings from the National Health andNutrition Examination Survey (NHANES) 1999 to 2000 // AmericanJournal of Kidney Diseases.
– 2004. – N.44. – P. 185-97.10389. Norris K., Vaughn С. The role of renin-angiotensin-aldosterone system inchronic kidney disease // Expert. Rev. Cardiovasc. Ther. - 2003. - v.1, №1.P. 51-63.90.Oliveras A., Armario P., Sierra C., et al. Urinary albumin excresion atfollow-up predicts cardiovascular outcomes in subjects with resistanthypertension // Am J Hypertens. – 2013. – Vol.26, N.9.
– P. 1148-1154.91. Orth S.R. Smoking and the kidney // J. Am. Soc. Nephrol. - 2002. - Vol.13. - P. 1663-1672.92.Orth S.R. Smoking and the kidney // J. Am. Soc. Nephrol. – 2002. – N. 13.– P. 1663-1672.93.Palatini P., Mormino P., Mos L., et al. Microalbuminuria, renal function anddevelopment of sustained hypertension: a longitudinal study in the earlystage of hypertension // J Hypertens.
– 2005. – N.23. – P. 175-82.94.Parving H., Mogensen C., Jensen H., Evrin P. Increased urinary albuminexcretion rate in benign essential hypertention // Lancet. – 1974. – N.1. – P.1190-1192.95. Perdinelli R. Microalbuminuria in Hypertension // Nephron. – 1996. –N.73. – P. 499-505.96.Pinto-Siersma S.J., Mulder J., Janssen W.M. et al. Smoking is related toalbuminuria and abnormal renal function in nondiabetic persons // Ann.Intern. Med.
– 2000. – N.133. – P. 585-591.97.Pontremoly R., Sofia A., Ravera M., et al. Prevalence and clinical correlatesof microalbuminuria in essential hypertension: the MAGIC Study:Microalbuminuria:AGenovaInvestigaiononComplications//Hypertension. – 1997. – N.30. – P. 1135-1143.98.Prving H, Lewis J, Ravid M, Remuzzi G, Hunsicker L: Prevalence and riskfactors for microalbuminuria in a referred cohort of type II diabetic patients:a global perspective // Kidney Int. – 2006.
– N.69. – P. 2057–2063.10499.Puilope L., Alcazar J., Rodicio J. Renal consequences of arterialhypertension // J Hypertens. – 1992. – N.10, Suppl.7. – P. 85-90.100. Randers E, Kristensen JH, Erlandsen EJ, Danielsen H. Serum cystatin Cas a marker of the renal function // Scand J Clin Lab Invest. – 1998. – Vol.58, N. 7. – P. 585-592.101.Ritz E., Dikow R., Ruilope L.M. Renal dysfunction as a cardiovascularrisk factor // Curr. Hypertens.
Rep. - 2002. - Vol. 4. - P. 365-368.102.Rutkowski B. Changing pattern of end-stage renal failure in Central andEastern Europe // Nephrol. Dial. Transplant. - 2002. - Vol. 15. - P. 156-160.103. Schaeffher E.S., KurthТ., Curhan G.C. et al. Cholesterol and the risk ofrenal dysfunction in apparently healthy men // J. Am. Soc. Nephrol. – 2003.– N.14. – P. 2084-2091.104. Schiepati A., Remuzzi G. Chronic renal disease as a public healthproblem: Epidemiology, social and economic implications // Kidney Int.
2005. - v. 68, Suppl. 98. - P. 7-10.105.Schiepati A., Remuzzi G. Chronic renal disease as a public healthproblem: Epidemiology, social and economic implications // Kidney Int. 2005. - Vol. 68, Suppl. 98. - P. S7-S10.106.Schmieder RE Schrader J, Zidek W et al. Low-grade albuminuria andcardiovascular risk: what is the evidence? // Clin Res Cardiol. – 2007. –Vol.96, N.5.
– P. 247-257.107. Schuck O, Teplan V, Jabor A et al. Glomerular filtration rate estimationin patients with advanced chronic renal insufficiency based on serumcystain C levels // Nephron Clin Pract. – 2003. – Vol. 93, N.4. – P. 122-123.108. Schuck O, Teplan V, Sibova J, Stollova M.
Predicting the glomerularfiltration rate from serum creatinine, serum cystatin C and the Cockcroftand Gault formula with regard to drug dosage adjustment // Int J ClinPharmacol Ther. – 2004. – Vol. 42, N. 2. – P. 97- 103.105109. Shlipak M.G., Stehman B.C., Fried L.F. et al. The presence of frailty inelderly persons with chronic renalinsufficiency // Am. J. Kidney Dis. –2004. – Vol.43, N.5.
– P. 861–867.110.Shlipak MG, Katz R, Sarnak MJ et al. Cystatin C and prognosis forcardiovascular and kidney outcomes in elderly persons without chronickidney disease // Ann Intern Med. – 2006. – N.145. – P. 237–246.111. Singh A., Farag Y., Mittal B. et al. Epidemiology and risk factors ofchronic kidney disease in India – results from the SEEK (Screening andEarly Evaluation of Kidney Disease) study // BMC Nephrology.
– 2013. –N.14. – P. 1-10.112. Singh A., Satchell S. Microalbuminuria: causes and implications //Pediatr Nephrol. – 2011. – Vol.26, N.11. – P. 1957-1965.113.Sjostrom P., Tidman M., Jones I. Determination of the production rateand non-renal clearance of cystatin C and estimation of the glomerularfiltration rate from the serum concentration of cystatin C in humans // ScandJ Clin Lab Invest. – 2005. – N.65. – P.
111–124.114. Smith JM, Mott SA, Hoy WE. Status of chronic kidney diseaseprevention programs: International Federation of Kidney FoundationMembers 2005/2007 // Kidney Int. – 2008. – N.74. – P. 1516-1525.115. Snyder J., Foley R., Collins A. Prevalence of CKD in the United States:a sensitivity analysis using the National Health and Nutrition ExaminationSurvey (NHANES) 1999-2004 // Am. J. Kidney Dis. – 2009. – Vol.53, N.2.– P.
218-228.116. Sontrop J.M., Dixon S.N., Garg A.X., Buendia-Jimenez I. et al.Associationbetweenwaterintake,chronickidneydisease,andcardiovascular disease: a cross-sectional analysis of NHANES data // Am.J. Nephrol. – 2013. – Vol. 37, N.5. – P. 434-442.106117. Stengel B., Tarver C.M., Powe N.R. et al. Lifestyle factors, obesity andthe risk of chronic kidney disease // Epidemiology. – 2003. – Vol.
14, N.4.– P. 479–487.118. Stidley C., Shan V., Narva A. A population-based, cross-sectional surveyof the Zuni Pueblo: a collaborative approach to an epidemic of kidneydisease // Am J Kidney Dis. – 2002. – N.39. – P. 358-368.119. Stuveling E.M., Bakker S.J., Hilige H.X. et al. Biochemical risk markers:a novel area for better prediction of renal risk? // Nephrol Dial Transplant. –2005. – N.20. – P. 497-508.120.Sukhova G.K., Wang B., Libby P., Pan J., Zhang Y.1.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
